A refined identity enhances communication of the institute's research priorities to both internal and external stakeholders.
About | IMMA
Established in 1984, the Edison Biotechnology Institute (EBI) began as an interdisciplinary biomedical research center within ºÚÁϳԹÏ. In 2024, the ºÚÁÏ³Ô¹Ï Board of Trustees approved EBI's transition into the Heritage College of Osteopathic Medicine, marking a significant milestone in its evolution.
Following extensive consultation with institute leadership and members, a formal proposal was submitted to the ºÚÁÏ³Ô¹Ï Vice President for Research and Creative Activity to rename the institute as the Institute for Molecular Medicine and Aging (IMMA). This change reflects a more focused mission:
“To conduct cutting-edge cellular and molecular research focused on the aging process, including advancing cancer research and driving drug discovery.â€
New Strategic Advantages
-
Increased Focus
-
Reduced Redundancy
IMMA compliments, rather than overlaps with, other research institutes within the Heritage College of Osteopathic Medicine.
-
Strategic Alignment
The research focus now aligns with the ºÚÁϳԹÏ's Discover Pillar of the Dynamic Strategy on Healthy Aging, positioning IMMA as a leader in molecular aging research.
-
Our Position
With a sharpened focus on molecular aging pathways, cancer, and drug discovery, IMMA is poised to strengthen its strategic position, leverage existing expertise, and expand funding opportunities. This transformation underscores ºÚÁϳԹÏ's commitment to advancing scientific discovery and developing targeted interventions to promote healthy aging at the molecular level.